Priority Review for Bayer's Drug - Analyst Blog

By
A A A

Bayer 's ( BAYRY ) Healthcare unit recently announced that its oncology candidate regorafenib, was granted priority review by the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients suffering from unresectable and/or metastatic gastrointestinal stromal tumors (GIST).

In Dec 2012, Bayer Yakuhin Ltd., Bayer's Japanese subsidiary, submitted a marketing authorization application for regorafenib to the MHLW in Japan. The company had earlier submitted a marketing application for the candidate in Japan for the treatment of colorectal cancer (CRC) and had received priority review in Aug 2012.

Bayer is seeking approval of the candidate on the basis of data from a phase III study (GRID: n=199), which evaluated patients suffering from metastatic and/or unresectable gastrointestinal stromal tumors. The disease had progressed in the evaluated patients in spite of being previously treated with Novartis ' ( NVS ) Gleevec and Pfizer 's ( PFE ) Sutent.

Regorafenib is already available in the US, under the brand name of Stivarga, for treating patients suffering from metastatic colorectal cancer (mCRC), whose disease had progressed even after treatment with standard drugs prescribed for the disease. A couple of days back, Stivarga was approved for the GIST indication as well in the US. Stivarga's label for the GIST indication in the US carries a boxed warning citing the risk of hepatotoxicity.

Bayer is also seeking EU approval of regorafenib for the treatment of mCRC.

Bayer, a large cap pharma company, currently carries a Zacks Rank #2 (Buy). Another large cap pharma stock Eli Lilly and Company ( LLY ) also carries a comparable rank.



BAYER A G -ADR (BAYRY): Free Stock Analysis Report

LILLY ELI & CO (LLY): Free Stock Analysis Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

PFIZER INC (PFE): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: BAYRY , CRC , LLY , NVS , PFE

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Budgeting for Baby
Budgeting for Baby                  
A Home to Retire In
A Home to Retire In                 

Stocks

Referenced

100%
100%
89%

Most Active by Volume

41,068,606
  • $16.953 ▼ 0.57%
35,290,476
  • $13.4899 ▼ 4.93%
30,770,744
  • $14.628 ▼ 1.10%
29,868,930
  • $76.76 ▼ 2.88%
28,308,024
  • $97.60 ▼ 1.20%
25,662,102
  • $3.445 ▼ 1.29%
23,857,337
  • $25.11 ▼ 0.24%
22,633,055
  • $99.704 ▼ 1.04%
As of 10/1/2014, 12:33 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com